An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact®), results of phase III and IV clinical studies

Haemophilia

Volumn 17, Issue 3, 2011, Pages 439-445

  Mauser Bunschoten, E P ^a   Kleine Budde, I ^b   Lopaciuk, S ^c   Koopman, M M W ^b,d   Van Der Meer, F J M ^e   Novakova I R O ^f   Ypma, P ^g   Van Der Linden, P W G ^h   Windyga, J ^c   Strengers, P F W ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g HAGA HOSPITAL   (Netherlands)

^h Department of Orthopaedic Surgery   (Netherlands)

Author keywords

Bleeding disorder; Clinical study; Factor IX; Haemophilia B; Monoclonal purified; Plasma product; Treatment

Indexed keywords

BLOOD CLOTTING FACTOR 9 CONCENTRATE;

ADULT; ALLERGIC DISEASE; ARTICLE; BLEEDING; COST CONTROL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; FOLLOW UP; HEMOSTASIS; HIGH RISK PATIENT; HOT FLUSH; HUMAN; IN VIVO STUDY; NETHERLANDS; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POLAND; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOEMBOLISM; THROMBOSIS; VIRUS INFECTION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; BLOOD LOSS, SURGICAL; FACTOR IX; FOLLOW-UP STUDIES; HEMOPHILIA B; HEMOSTASIS, SURGICAL; HUMANS; MIDDLE AGED; NETHERLANDS; POLAND; POSTOPERATIVE HEMORRHAGE; YOUNG ADULT;

EID: 79955141563     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02453.x     Document Type: Article

References (20)

1. Gray E, Tubbs J, Thomas S et al. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity. Thromb Haemost 1995; 73: 675-9.
2. Foster PR, Welch AG, McLean C et al. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang 2000; 78: 86-95.
3. Cervenakova L, Brown P, Hammond DJ, Lee CA, Saenko EL. Factor VIII and transmissible spongiform encephalopathy: the case for safety. Haemophilia 2002; 8: 63-75.
4. Tateishi J, Kitamoto T, Mohri S et al. Scrapie removal using Planova virus removal filters. Biologicals 2001; 29: 17-25.
5. The European Agency for the Evaluation of Medicinal Products. CPMP 198/95, Final: 'Note for guidance to assess efficacy and safety of human plasma derived Factor VIII:C and Factor IX:C products in clinical trials in haemophiliacs before and after authorisation'. 1996.
6. The European Agency for the Evaluation of Medicinal Products. CPMP/BPWG/198/95, rev. 1: 'Note for guidance on the clinical investigation of human plasma derived factor VIII and IX products'. 2000.
7. Mannucci PM, Bauer KA, Gringeri A et al. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood 1990; 76: 2540-5.
8. Mannucci PM, Bauer KA, Gringeri A et al. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate. Br J Haematol 1991; 79: 606-11.
9. Bruhn HD, Conard J, Mannucci M et al. Multicentric evaluation of a new assay for prothrombin fragment F1+2 determination. Thromb Haemost 1992; 68: 413-7.
10. Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost 1991; 66: 384-6.
11. Poon MC, Aledort LM, Anderle K, Kunschak M, Morfini M. Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. Transfusion 1995; 35: 319-23.
12. Ewenstein BM, Joist JH, Shapiro AD et al. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002; 42: 190-7.
13. Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600-6.
14. Hoffman M, Harger A, Lenkowski A, Hedner U, Roberts HR, Monroe DM. Cutaneous wound healing is impaired in hemophilia B. Blood 2006; 108: 3053-60.
15. Bond M, Jankowski M, Patel H et al. Biochemical characterization of recombinant factor IX. Semin Hematol 1998; 35: 11-7.
16. Bjorkman S, Folkesson A, Berntorp E. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting. Haemophilia 2007; 13: 2-8.
17. White G, Shapiro A, Ragni M et al. Clinical evaluation of recombinant factor IX. Semin Hematol 1998; 35: 33-8.
18. White GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997; 78: 261-5.
19. Hrinda ME, Huang C, Tarr GC, Weeks R, Feldman F, Schreiber AB. Preclinical studies of a monoclonal antibody-purified factor IX, Mononine. Semin Hematol 1991; 28: 6-14.
20. Rodrigues H, Giles K, Sefton L, Griffin V, Duxbury M, Letwin B. Analytical characterization of recombinant human factor IX (rhFIX). Thromb Haemost 1995; 73: 1206.